Atlas Trials

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Clinical trial NCT01636401 · COMPLETED

Trial details

NCT number
NCT01636401
Sponsor
Daewoong Pharmaceutical Co. LTD.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
COPD
Start date
2012-08-01
Primary completion
2013-05-01

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.